These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 15146390)

  • 21. A NOVEL MUTATION IN NPR2 GENE IN A PATIENT WITH ACROMESOMELIC DYSPLASIA, MAROTEAUX TYPE.
    Sag SO; Gorukmez O; Topak A; Gorukmez O; Ture M; Sahinturk S; Gulten T; Yakut T
    Genet Couns; 2015; 26(2):219-25. PubMed ID: 26349192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Translational research of C-type natriuretic peptide (CNP) into skeletal dysplasias.
    Yasoda A; Nakao K
    Endocr J; 2010; 57(8):659-66. PubMed ID: 20567091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heterozygous mutations in natriuretic peptide receptor-B (NPR2) gene as a cause of short stature.
    Wang SR; Jacobsen CM; Carmichael H; Edmund AB; Robinson JW; Olney RC; Miller TC; Moon JE; Mericq V; Potter LR; Warman ML; Hirschhorn JN; Dauber A
    Hum Mutat; 2015 Apr; 36(4):474-81. PubMed ID: 25703509
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Further defining the clinical and molecular spectrum of acromesomelic dysplasia type maroteaux: a Turkish tertiary center experience.
    Simsek-Kiper PO; Urel-Demir G; Taskiran EZ; Arslan UE; Nur B; Mihci E; Haliloglu M; Alanay Y; Utine GE; Boduroglu K
    J Hum Genet; 2021 Jun; 66(6):585-596. PubMed ID: 33288834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An activating mutation in the kinase homology domain of the natriuretic peptide receptor-2 causes extremely tall stature without skeletal deformities.
    Hannema SE; van Duyvenvoorde HA; Premsler T; Yang RB; Mueller TD; Gassner B; Oberwinkler H; Roelfsema F; Santen GW; Prickett T; Kant SG; Verkerk AJ; Uitterlinden AG; Espiner E; Ruivenkamp CA; Oostdijk W; Pereira AM; Losekoot M; Kuhn M; Wit JM
    J Clin Endocrinol Metab; 2013 Dec; 98(12):E1988-98. PubMed ID: 24057292
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A human skeletal overgrowth mutation increases maximal velocity and blocks desensitization of guanylyl cyclase-B.
    Robinson JW; Dickey DM; Miura K; Michigami T; Ozono K; Potter LR
    Bone; 2013 Oct; 56(2):375-82. PubMed ID: 23827346
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel Loss-of-Function Mutations in
    Wu J; Wang M; Jiao Z; Dou B; Li B; Zhang J; Zhang H; Sun Y; Tu X; Kong X; Bai Y
    Front Genet; 2022; 13():823861. PubMed ID: 35368703
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification and functional characterization of two novel NPR2 mutations in Japanese patients with short stature.
    Amano N; Mukai T; Ito Y; Narumi S; Tanaka T; Yokoya S; Ogata T; Hasegawa T
    J Clin Endocrinol Metab; 2014 Apr; 99(4):E713-8. PubMed ID: 24471569
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Catalytically Active Guanylyl Cyclase B Requires Endoplasmic Reticulum-mediated Glycosylation, and Mutations That Inhibit This Process Cause Dwarfism.
    Dickey DM; Edmund AB; Otto NM; Chaffee TS; Robinson JW; Potter LR
    J Biol Chem; 2016 May; 291(21):11385-93. PubMed ID: 26980729
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduced ability of C-type natriuretic peptide (CNP) to activate natriuretic peptide receptor B (NPR-B) causes dwarfism in lbab -/- mice.
    Yoder AR; Kruse AC; Earhart CA; Ohlendorf DH; Potter LR
    Peptides; 2008 Sep; 29(9):1575-81. PubMed ID: 18554750
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Hormones and osteoporosis update. Effects of natriuretic peptides on endochondral bone growth].
    Yasoda A; Nakao K
    Clin Calcium; 2009 Jul; 19(7):1003-8. PubMed ID: 19567998
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overgrowth syndrome associated with a gain-of-function mutation of the natriuretic peptide receptor 2 (NPR2) gene.
    Miura K; Kim OH; Lee HR; Namba N; Michigami T; Yoo WJ; Choi IH; Ozono K; Cho TJ
    Am J Med Genet A; 2014 Jan; 164A(1):156-63. PubMed ID: 24259409
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acromesomelic Dysplasia, Type Maroteaux: Impact of Long-Term (8 Years) High-Dose Growth Hormone Treatment on Growth Velocity and Final Height in 2 Siblings.
    Arya VB; Raj M; Younes M; Chapman S; Irving M; Kapoor RR; Buchanan CR
    Horm Res Paediatr; 2020; 93(5):335-342. PubMed ID: 33238275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. C-type natriuretic peptide plasma levels are elevated in subjects with achondroplasia, hypochondroplasia, and thanatophoric dysplasia.
    Olney RC; Prickett TC; Espiner EA; Mackenzie WG; Duker AL; Ditro C; Zabel B; Hasegawa T; Kitoh H; Aylsworth AS; Bober MB
    J Clin Endocrinol Metab; 2015 Feb; 100(2):E355-9. PubMed ID: 25387261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biallelic cGMP-dependent type II protein kinase gene (
    Díaz-González F; Wadhwa S; Rodriguez-Zabala M; Kumar S; Aza-Carmona M; Sentchordi-Montané L; Alonso M; Ahmad I; Zahra S; Kumar D; Kushwah N; Shamim U; Sait H; Kapoor S; Roldán B; Nishimura G; Offiah AC; Faruq M; Heath KE
    J Med Genet; 2022 Jan; 59(1):28-38. PubMed ID: 33106379
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An Activating Deletion Variant in the Submembrane Region of Natriuretic Peptide Receptor-B Causes Tall Stature.
    Lauffer P; Miranda-Laferte E; van Duyvenvoorde HA; van Haeringen A; Werner F; Boudin E; Schmidt H; Mueller TD; Kuhn M; van der Kaay DCM
    J Clin Endocrinol Metab; 2020 Jul; 105(7):2354-66. PubMed ID: 32282051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. C-type natriuretic peptide in growth: a new paradigm.
    Olney RC
    Growth Horm IGF Res; 2006 Jul; 16 Suppl A():S6-14. PubMed ID: 16716628
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gastrointestinal tract disorder in natriuretic peptide receptor B gene mutant mice.
    Sogawa C; Abe A; Tsuji T; Koizumi M; Saga T; Kunieda T
    Am J Pathol; 2010 Aug; 177(2):822-8. PubMed ID: 20616347
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiac hypertrophy in transgenic rats expressing a dominant-negative mutant of the natriuretic peptide receptor B.
    Langenickel TH; Buttgereit J; Pagel-Langenickel I; Lindner M; Monti J; Beuerlein K; Al-Saadi N; Plehm R; Popova E; Tank J; Dietz R; Willenbrock R; Bader M
    Proc Natl Acad Sci U S A; 2006 Mar; 103(12):4735-40. PubMed ID: 16537417
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lysophosphatidic acid inhibits C-type natriuretic peptide activation of guanylyl cyclase-B.
    Abbey SE; Potter LR
    Endocrinology; 2003 Jan; 144(1):240-6. PubMed ID: 12488350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.